Roluperidone (MIN-101)

About Minerva Neurosciences

Minerva Neurosciences is a publicly traded, clinical-stage biotech company focused on addressing significant unmet medical needs in central nervous system disorders, particularly schizophrenia and Parkinson's disease. Founded in 2007, the company's core strategy centers on its specialized expertise in clinical trial design, aiming to demonstrate clear patient benefit through carefully selected endpoints and patient populations. While currently pre-revenue, its value proposition lies in its ability to potentially de-risk late-stage development in challenging CNS indications. The company faces the critical challenge of advancing its pipeline through clinical milestones with limited financial resources.

Therapeutic Areas

Other Schizophrenia (Negative Symptoms) Drugs